According to Vaxart's latest financial reports the company has $39.71 M in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $39.71 M | -58.51% |
2022-12-31 | $95.71 M | -42.51% |
2021-12-31 | $0.16 B | 31.23% |
2020-12-31 | $0.12 B | 837.97% |
2019-12-31 | $13.52 M | 18.07% |
2018-12-31 | $11.45 M | |
2017-06-30 | $38.6 M | -44.06% |
2016-06-30 | $69 M | 19.79% |
2015-06-30 | $57.6 M | -29.5% |
2014-06-30 | $81.7 M | 22.31% |
2013-06-30 | $66.8 M | |
2011-12-31 | $96.38 M | -10.89% |
2010-12-31 | $0.10 B | -9.1% |
2009-12-31 | $0.11 B | -8.7% |
2008-12-31 | $0.13 B | -40.54% |
2007-12-31 | $0.21 B | 84.63% |
2006-12-31 | $0.11 B | 11.03% |
2005-12-31 | $0.10 B | 3.71% |
2004-12-31 | $0.10 B | -10.93% |
2003-12-31 | $0.11 B | 123.74% |
2002-12-31 | $51.73 M | -60.56% |
2001-12-31 | $0.13 B |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Nymox Pharmaceutical NYMX | $0.13 M | -99.67% | Bahamas |
NRC Health
NRC | $6.65 M | -83.25% | ๐บ๐ธ USA |